PHESGO offers a different way to get your HER2-positive breast cancer treatment. It brings together PERJETA® (pertuzumab) and Herceptin® (trastuzumab) in a single injection just under the skin.
PHESGO also contains a protein called hyaluronidase that helps your body absorb these 2 medicines and allows them to be given as a single injection in about 5 minutes.* How is that possible? >
PHESGO is given as part of a complete treatment regimen for HER2+ breast cancer that includes chemotherapy.
*Your first dose is given in ~8 minutes. This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
PHESGO contains the same medicines that are inside PERJETA and Herceptin. The main difference between them is how it’s given.
PERJETA and Herceptin are given as 2 separate infusions, either through an IV or through a port, whereas PHESGO is given as one injection just under the skin in the thigh.
This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
If you’re already receiving PERJETA + Herceptin, your doctor may be able to switch you to PHESGO if they think it’s right for you.
Call the Patient Resource Center for answers to your questions about PHESGO or other resources from Genentech.
Monday-Friday, 6am-5pm PST
This is not meant to replace the advice of your healthcare team.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.